The HHS Panel on #Antiretroviral Guidelines for Adults and Adolescents with #HIV welcomes seven new scientific members and one new community member. To learn more about each member: bit.ly/4c4jThp

Our paper on 2 year efficacy and safety data for lenacapavir for people with multidrug resistant HIV, were viremic and had limited treatment options now published Bottom line...remarkable virologic suppression rates persist and well tolerated. academic.oup.com/cid/advance-ar…

Interesting study showing that GLP-1 agonist- semaglutide- reduced mortality (feom cardiovascular and non cardiovascular causes including death from COVID) in users versus non users. The GLP-1s have multimorbidity benefits that are only being unearthed! jacc.org/doi/10.1016/j.…

Metabolic syndrome increasingly common among people with HIV. A nice resource for providers... we just published...discusses contemporary ART (including lenacapavir) and their interactions with hypertension, Diabetes, antiobesity, lipid lowering drugs tandfonline.com/doi/full/10.10…